01875 Should I Buy

The analyst rating for WUXI BIO is "Buy" according to Daiwa's research report. The reason for this positive rating is the anticipated benefits from WUXI XDC's acquisition of at least 60% of BIODLINK-B. This acquisition is expected to expand WUXI XDC's business, enhance operational production capacity in China, enrich its project portfolio, enlarge its customer base, and consolidate its leading market position in the ADC contract development and manufacturing organization sector. These factors contribute to a favorable outlook for WUXI BIO.